Patients diagnosed with multiple myeloma almost always relapse after treatment. Moreover, the time spent in remission is reduced after every relapse, indicating a constantly worsening condition of the patients. The choice of regimen for a relapsed patient depends on variety of factors, including previous therapy, general physical performance status, aggressiveness of the relapse, and more.
A synthetic control arm may accelerate the understanding of which treatment is favourable to a selected patient group and provide an immediate clinical benefit. The case study shows the potential for effective use of Real World Data to support a clinical trial.